Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXCAN Pharma(AXCA)..A GUT FEELING! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (17)	8/24/2000 11:39:10 PM
From: Sleepman	Read Replies (4) \| Respond to of 46

I guess that is what happens when you have such a thinly traded stock. I have not yet pulled the trigger on this one. In buying Scandipharm, they now have a working company and products for distribution in the US. I still think that the main reason to buy now would be the H. pylori treatment. I do have reservations about the future of Photoferin, and would not factor that into my equation at all. The reason is that I is not clear how effective it will really be in the end for control of Barretts. Apparantly, there are significant reports that only the surface of the the esophagus is acutally changed by the process, and lower layers of the epithelium may remain as barretts and still be a malignant risk. I also am concerned about the debt load. Do you have any thoughts on that? Thanks, Dan